7MW-3711

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug Name7MW-3711
Drug Alias Name7MW37117-MW-3711
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Disulfide bond linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MF6 payload
Mechanisms of ActionAnti-CD276DNA topoisomerase I inhibitors
TargetsCD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung Carcinoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A